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Introduction: Tiotropium, a once-daily long-acting anticholinergic agent, has been shown to be
an efficacious and safe add-on treatment for adults with symptomatic asthma, despite treat-
ment with inhaled corticosteroids (ICS). A large proportion of asthmatic adolescents have
symptomatic disease despite a wide range of therapeutic options. We investigated the efficacy
and safety of three doses of tiotropium, administered in the evening (via Respimat SoftMist
inhaler), versus placebo in asthmatic adolescents symptomatic despite ICS treatment.
Methods: This randomised, double-blind, placebo-controlled, incomplete crossover study
evaluated once-daily tiotropium 5 μg, 2.5 μg and 1.25 μg versus placebo in three 4-week treat-
ment periods. Primary efficacy end point was change in peak forced expiratory volume in
1 s within 3 h post-dose from baseline (peak FEV1(0e3h)).) 351 458 5699; fax: þ49 (0) 351 458 4334.
g@uniklinikum-dresden.de (C.Vogelberg).
14.06.011
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
nd/3.0/).
Tiotropium add-on in adolescents with symptomatic asthma 1269Results: From 139 enrolled patients, 105 were randomised to receive one of four treatment
sequences. Peak FEV1(0e3h) response for tiotropium 5 μg was significantly greater versus pla-
cebo (p Z 0.0043). Trough FEV1 responses were significantly greater for tiotropium 5 μg
(p < 0.00001) and 1.25 μg (pZ 0.0134) versus placebo, but not for 2.5 μg (pZ 0.0975), while
FEV1 area under the curve(0e3h) responses were significant for all doses (pZ 0.00001e0.0398).
Overall incidence of adverse events was balanced across treatment groups, with no dose-
dependent observations. The majority of adverse events were mild to moderate in intensity.
Conclusion: This first study of tiotropium in adolescents with symptomatic asthma demon-
strates that tiotropium is well tolerated and efficacious as add-on to maintenance treatment
with ICS.
ClinicalTrials.gov identifier; NCT01122680.
ª 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Asthma affects 1e18% of the global population [1] and is
linked to approximately one in every 250,000 deaths world-
wide, many of which are preventable [1]. It is one of the
leading causes of childhood morbidity in developed countries
[2]. In the USA, it has been estimated that 10% of children
aged 12e18 years have asthma, with over half of these pa-
tients having symptomatic disease [3]. There are various
reasons for this, including: poor adherence to treatment,
regarded as most relevant within this specific age group; lack
of responsiveness to treatment; genetic components; and
misdiagnoses [4,5]. Therefore, a need remains for alterna-
tive and potentially improved treatment options that may
help to overcome some of these limitations [4].
At least 40% of patients with asthma remain symptom-
atic despite treatment with inhaled corticosteroids (ICS) as
monotherapy or in combination with long-acting b2-agonists
(LABAs) [6e8]. The common treatment approach for these
patients is a dose increase of ICS, with additional medica-
tions such as LABAs, leukotriene modifiers, sustained-
release methylxanthines, oral glucocorticosteroids or anti-
immunoglobulin E prescribed according to individual
needs, as outlined in the National Asthma Education and
Prevention Program guidelines [9]. However, the high pro-
portion of asthmatic patients who do not achieve control
with these medications suggests there is a need for alter-
native additional treatments, such as bronchodilator
maintenance therapy added to ICS.
A meta-analysis of 10 randomised, double-blind,
controlled studies of asthmatic patients with severe exac-
erbations demonstrated that the short-acting anticholin-
ergic bronchodilator ipratropium bromide, as add-on
therapy to short-acting b2-agonists, improves lung function
and reduces hospital admissions [10]. The long-term man-
agement of asthma by ipratropium bromide has not been
fully elucidated, but global guidelines recommend short-
acting anticholinergic bronchodilators, in combination
with short-acting b2-agonists, as reliever medication for
asthmatic patients [1].
The long-acting anticholinergic bronchodilator tio-
tropium bromide has demonstrated efficacy and tolerability
as a once-daily dose in adult patients with chronic
obstructive pulmonary disease [11,12]. More recently intwo proof-of-concept studies, treatment with once-daily
tiotropium 5 μg (via the Respimat SoftMist inhaler
[Boehringer Ingelheim, Ingelheim am Rhein, Germany],
hereinafter referred to as tiotropium Respimat) for 8e16
weeks improved lung function in patients with symptomatic
asthma despite receiving ICS with or without LABAs [13,14].
Furthermore, in two replicate placebo-controlled, Phase III
studies, once-daily tiotropium Respimat 5 μg has been
shown to reduce the risk of exacerbations and improve lung
function in adult patients with symptomatic asthma despite
the use of ICS plus LABAs [15].
To date, no study data have been published describing the
pharmacology, efficacy or safety of tiotropium Respimat
add-on to at least ICS maintenance therapy in children or
adolescents with asthma. Lung function and safety findings
are presented here from the first study of tiotropium
Respimat add-on therapy to ICSwith or without leukotriene
modifiers in adolescents with symptomatic asthma.Methods
Study design
This randomised, double-blind, placebo-controlled, dose-
ranging, Phase II, incomplete crossover study was conduct-
ed at 19 centres in five countries (Germany, Latvia,
Lithuania, Slovenia and the USA) from June 2010 to April
2011. After a 4-week run-in period, patients aged 12e17
years with moderate persistent asthma on medium-dose ICS
were randomised in a 1:1:1:1 ratio to receive once-daily
placebo or tiotropium 5 μg, 2.5 μg or 1.25 μg, all delivered
via the Respimat SoftMist inhaler, every evening during
each of the three 4-week treatment periods (for a total of 12
weeks, without washout between treatment periods) ac-
cording to an incomplete crossover design (Fig. 1). Clinic
visits were scheduled at screening (Visit 0), prior to the 4-
week run-in period (Visit 1), every 4 weeks during the 12-
week treatment period (Visits 2e5) and at the end of the
3-week follow-up period (Visit 6). Background medium-dose
ICS with or without leukotriene receptor antagonists were
taken throughout the study with no change in dose. Patients
receiving ICS plus LABA discontinued the LABA prior to the
run-in period. Open-label short-acting b2-agonist salbutamol
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Figure 1 Study design. FEV1, forced expiratory volume in 1 s; PEF, peak expiratory flow.
1270 C. Vogelberg et al.(albuterol) hydrofluoroalkane metered-dose inhaler (100 μg
per puff) was provided as rescue medication for use during
the study. Patients receiving placebo Respimat continued
with background ICS with or without leukotriene receptor
antagonists throughout the study, and salbutamol was pro-
vided as rescue medication. At both screening and random-
isation, patients were trained in the correct use of the
Respimat SoftMist inhaler using placebo inhalation solu-
tion, and on all lung function test days, trial medication was
administered under the supervision of a clinician.
A fixed block randomisation was used to ensure that the
number of patients allocated to each treatment was
balanced. The order of assignment of patients to treatment
sequences at Visit 2 was also randomised. The random-
isation list was generated by Boehringer Ingelheim using a
validated system with a pseudo-random number generator
and a supplied seed number.
The study met all local legal and regulatory re-
quirements, followed the Declaration of Helsinki and con-
formed to Good Clinical Practice guidelines. All patients
and their parents/legal guardians gave written, informed
consent prior to enrolment into the study. The protocol was
approved by an independent ethics committee at each
study centre. The study was registered at www.
clinicaltrials.gov (NCT01122680).
Study population
Male and female outpatients aged 12e17 years with a
documented minimum 3-month history of asthma were
eligible for enrolment into this study. All patients were
symptomatic as defined by a seven-question Asthma Control
Questionnaire (ACQ-7) mean score of1.5 at screening (Visit
1) and prior to randomisation (Visit 2), had a pre-
bronchodilator forced expiratory volume in 1 s (FEV1) >60%
and 90% of the predicted normal [16], and had an FEV1 in-
crease of at least 12% and 200 mL from baseline
15e30min after 400 μg salbutamol at Visit 1. In patients aged
12e14 years, who are likely to have a smaller forced vital
capacity, positive reversibility testing could be based solely
on the relative (12%) post-bronchodilator response. Eligible
patients were non-smokers or had not smoked in the yearbefore enrolment. Key exclusion criteria were: a significant
respiratory medical condition, other than asthma (eg cystic
fibrosis), or congenital heart disease; an exacerbation or
acute respiratory tract infection in the 4 weeks prior to
screening or during the run-in period; and treatment with a
long-acting anticholinergic or systemic (oral or intravenous)
corticosteroid within 4 weeks prior to screening.
Study end points and assessments
The primary efficacy end point was peak FEV1 response
within 3 h after administration of the maintenance and
study drugs (peak FEV1(0e3h)) as a change from baseline
FEV1 at the end of each of the three 4-week treatment
periods. Secondary end points included: trough FEV1
response as a change from baseline pre-dose FEV1 at the
end of each of the three 4-week treatment periods
(measured just prior to the last administration of the ran-
domisation treatment); FEV1 area under the curve
(AUC)(0e3h) response; and pre-dose morning and evening
peak expiratory flow (PEF). As an additional exploratory
end point, control of asthma was assessed by ACQ-7 at the
end of each 4-week treatment period.
Lung function assessments were performed at 30 min,
1 h, 2 h and 3 h after inhalation of the study medication
during clinic visits at screening, at the end of the 4-week
run-in period and at the end of each 4-week treatment
period. At each time point, FEV1 was measured from a se-
ries of at least three spirometric manoeuvres that included
an acceptable test start and were free from artefacts such
as coughing, and the highest FEV1 from an acceptable
manoeuvre was recorded. Spirometers and their use,
including daily calibration, were required to meet American
Thoracic Society criteria. FEV1 and PEF were measured
using the Asthma Monitor (AM3; eResearch Technology
GmbH, Estenfeld, Germany), which was also used by pa-
tients as an e-diary. PEF means were determined in the last
week of each treatment period to avoid carry-over of pre-
vious treatment effects. Patients completed ACQ-7 at Visit
1 and then at every visit during the treatment period. It
comprised six questions for the patient and one question on
FEV1 for the clinic personnel [17].
Table 1 Baseline demographics and clinical characteris-
tics at screening (treated set).
Characteristic All treated patients
(n Z 105)
Gender, n (%)
Male 67 (63.8)
Female 38 (36.2)
Race, n (%)
White 102 (97.1)
Black/African-American 2 (1.9)
Asian 1 (1.0)
Ethnicity, n (%)
Not Hispanic/Latino 104 (99.0)
Hispanic/Latino 1 (1.0)
Mean age, years (SD)a 14.0 (1.5)
BMI, kg/m2 (SD) 21.0 (5.3)
Smoking history, n (%)
Never smoked 104 (99.0)
Ex-smoker 1 (1.0)
Duration of asthma, n (%)
<1 year 6 (5.7)
1e<3 years 24 (22.9)
3e<10 years 39 (37.1)
10e17 years 36 (34.3)
Concomitant pulmonary
therapies, n (%)b
Glucocorticoids 105 (100)
Inhaled 105 (100)
Intranasal 29 (27.6)
Oral 2 (1.9)
b2-adrenoceptor agonists 53 (50.5)
Long-acting 46 (43.8)
Short-acting 22 (21.0)
Leukotriene modifiers 24 (22.9)
Systemic antihistamines 21 (20.0)
Anti-allergic agents
(excluding corticosteroids)
11 (10.5)
Short-acting anticholinergics 2 (1.9)
BMI, body mass index; SD, standard deviation.
a Age range was 12e17 years.
b Received within the last 3 months before Visit 1.
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study based on the recorded information in the AM3 de-
vice and calculated as the number of AM3 entries indi-
cating study medication uptake divided by the number of
non-clinic days on treatment then multiplied by 100%.
The analysis of safety and tolerability was descriptive in
nature, and measured based on the incidence and intensity
of adverse events (AEs) and changes in 12-lead electro-
cardiogram (assessed during screening and at the end of the
treatment period), physical examination and vital signs,
including pulse rate and seated blood pressure.
Statistical analysis
Assuming a standard deviation of 228 mL, based on adult
data for within-patient difference in peak FEV1(0e3h) [14], a
sample size of 44 completed patients was required in order
to detect a treatment difference of 100 mL for the peak
FEV1(0e3h) response with 80% power. Using the equation
n Z 3*m/2, it was determined that 66 patients would be
needed for the incomplete block design used in this study
[18]. It was estimated that approximately 92 patients would
be required to be randomised in order to obtain 66
completer patients, allowing for a drop-out rate of almost
30%.
The primary efficacy analysis was performed using the
full analysis set, defined as all randomised patients who
were treated with at least one dose of study medication,
had baseline data and had at least one on-treatment effi-
cacy measurement after a 4-week treatment period. The
number of patients varied between treatment groups as
some patients had no evaluable data for 1 treatments due
to premature discontinuation of the study. The primary
analysis was a mixed model repeated measures analysis
that included ‘treatment’ and ‘period’ as fixed effects
(‘period’ as repeated) and ‘patient’ as a random effect.
Study baseline was included as a covariate. Adjusted mean
values were calculated, in addition to treatment contrasts,
with 95% confidence intervals and p values.
All secondary end points were analysed using the full
analysis set, unless otherwise stated, and a mixed model
repeated measures analysis. All calculated p values were
exploratory. Data are presented as adjusted mean change
from baseline after 4 weeks of treatment, unless noted
otherwise.
The treated set was used for safety evaluation and was
defined as all randomised patients who took at least one
dose of study medication.
Results
Overall, 139 adolescent patients were enrolled (see
Supplementary Fig. 1). Of these patients, 105 were rando-
mised to receive once-daily tiotropium Respimat 5 μg
(n Z 80), 2.5 μg (n Z 75) or 1.25 μg (n Z 75), or placebo
Respimat (nZ 75). The treated set therefore included all
randomised patients who received at least one dose of
study medication (n Z 105). Due to premature discontin-
uation during either the treatment period or the study, the
number of evaluable patients within the analysis sets varied
between treatments.A total of 97 patients completed all three treatment
periods. Of the eight patients who prematurely dis-
continued study medication, two discontinued due to AEs,
two due to non-compliance, one due to withdrawal of
consent, one due to randomisation error, one due to an
ACQ-7 score of <1.5 at Visit 2 and one as a result of patient
decision. Three patients discontinued study medication
while receiving tiotropium Respimat 5 μg, one while
receiving tiotropium Respimat 2.5 μg, three while
receiving tiotropium Respimat 1.25 μg and one while
receiving placebo Respimat. Overall, median compliance
ranged from 85% to 87% across the treatment groups.
Baseline demographics and disease characteristics
The baseline characteristics of all randomised patients at
screening are shown in Table 1. The study population was
predominantly male and white, and the mean age overall
Table 2 Disease characteristics measured during reversibility testing and at study site (treated set; n Z 105).
Reversibility testing (Visit 1) Study baseline (Visit 2)
Pre-bronchodilatora Post-bronchodilatorb Pre-dosec
Mean (SD) Mean (SD) Mean (SD)
FEV1
Predicted normal, mL 3397 (784) e e
Actual, mL 2642 (608) 3276 (714) 2742 (697)
Actual, % predicted normal 77.5 (6.6) 97.2 (10.5) 80.9 (10.3)
Reversibility, mLd e 653 (261) e
Reversibility, % of pre-bronchodilatore e 25.6 (11.2) e
Variation, %f e e 4.8 (13.5)
Mean PEF, L/min
Morning e e 346.5 (89.5)
Evening e e 370.3 (91.9)
Asthma Control Questionnaire e e 2.1 (0.4)
FEV1, forced expiratory volume in 1 s; PEF, peak expiratory flow; SD, standard deviation.
a Measured 10 min prior to inhalation of four puffs of salbutamol (100 μg per puff) at Visit 1.
b Measured 15e30 min after inhalation of four puffs of salbutamol (100 μg per puff) at Visit 1.
c Measured 10 min prior to inhalation of study medication at Visit 2.
d Calculated as: FEV1 post-bronchodilator  FEV1 pre-bronchodilator.
e Calculated as: 100  ([FEV1 post-bronchodilator/FEV1 pre-bronchodilator]  1).
f Calculated as: 100  ([FEV1 at Visit 2/post-bronchodilator FEV1 at Visit 1]  1).
1272 C. Vogelberg et al.was 14 years. One patient was an ex-smoker, but no pa-
tient smoked at randomisation. In 37.1% of patients, the
duration of asthma was between 3 and 10 years. A slightly
lower percentage (34.3%) of patients had an asthma
duration of 10e17 years, with the remainder (28.6%)
having an asthma duration of <3 years. Within 3
months before Visit 1, almost half of the study population
had received LABAs, almost a quarter had received
leukotriene modifiers and a fifth had received systemic
antihistamines.
Following salbutamol inhalation, an overall improve-
ment in FEV1 values was observed from the baseline pre-
bronchodilator FEV1 value of <90% after a 4-week run-in
period (Table 2). A post-bronchodilator FEV1 >90% of the
predicted normal [16] was recorded in 77.1% of patients,
and 20% of patients had FEV1 >80% but 90% of the pre-
dicted normal. The average reversibility, change in pre- to
post-bronchodilation, was 653 mL (25.6%). At Visit 2, FEV1
>90% of the predicted normal was reported in 18.1% of
patients, 38.1% of patients had FEV1 >80% but 90% of the
predicted normal, 41.0% of patients had FEV1 60% but
80% of the predicted normal, and only 2.9% of patients
had FEV1 <60%.Efficacy
Efficacy end points were assessed in the 104 patients
included in the full analysis set. Efficacy data were not
available for one patient who discontinued study medica-
tion during the first treatment period.
Primary end point
Overall, mean FEV1 at baseline was 2746 mL. The largest
adjusted mean peak FEV1(0e3h) response from baseline was
reported with tiotropium Respimat 5 μg (602 mL) (Fig. 2);this difference was significant compared with placebo
Respimat (113 mL; p Z 0.004). Smaller responses in the
adjusted mean peak FEV1(0e3h) response were associated
with tiotropium Respimat 2.5 μg and 1.25 μg (546 mL and
556 mL, respectively) compared with placebo Respimat
(489 mL). Treatment differences between tiotropium
Respimat 2.5 μg and 1.25 μg and placebo Respimat did
not reach statistical significance (57 mL [p Z 0.1484] and
67 mL [p Z 0.0664], respectively).
Secondary end points
Trough FEV1 response with tiotropium Respimat
 was also
greater than with placebo Respimat (adjusted mean:
5 μg, 442 mL; 2.5 μg, 353 mL; 1.25 μg, 384 mL; placebo,
292 mL) (Fig. 2). The largest response in trough FEV1 over
placebo Respimat was observed with tiotropium
Respimat 5 μg and was statistically significant (adjusted
mean of difference: 151 mL; p < 0.0001). Lower treat-
ment differences were observed between tiotropium
Respimat 2.5 μg and 1.25 μg and placebo Respimat
(62 mL [p Z 0.0975] and 92 mL [p Z 0.0134],
respectively).
The adjusted mean FEV1 AUC(0e3h) response was greater
for all three tiotropium Respimat groups (5 μg, 497 mL;
2.5 μg, 434 mL; 1.25 μg, 455 mL) compared with placebo
Respimat (363 mL) (Fig. 3). The adjusted mean of differ-
ence in FEV1 AUC(0e3h) response over placebo Respimat

was highest with tiotropium Respimat 5 μg and statisti-
cally significant (133 mL; p Z 0.001).
The maximum FEV1 response (505 mL) was observed
1 h after tiotropium Respimat 5 μg inhalation (Fig. 4). At 2
or 3 h after inhalation, the maximum FEV1 response was
reached in the tiotropium Respimat 2.5 μg and 1.25 μg and
placebo Respimat groups (2.5 μg, 489 mL; 1.25 μg, 467 mL;
placebo, 396 mL). FEV1 responses following tiotropium
Respimat 5 μg were superior to placebo Respimat at all
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inhalation; p  0.014). There was a significant difference
between tiotropium Respimat 5 μg and 2.5 μg in adjusted
mean FEV1 response up to 1 h after study drug inhalation in
favour of the higher dose (890 mL; 95% confidence interval:
22e157 mL).
In the overall study population, morning and evening
mean PEF at baseline (Visit 2) were 346 L/min and 370 L/
min, respectively. After 4 weeks of randomised treatment,
the adjusted mean PEF response for placebo was 7.3 L/min
in the morning and 0.552 L/min in the evening (Fig. 5).
Morning PEF response for all three tiotropium Respimat
groups was superior to placebo Respimat (adjusted mean
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1274 C. Vogelberg et al.Safety and tolerability
Tiotropium Respimat appeared well tolerated across all
three doses. There was a slightly higher rate of AEs in the
tiotropium Respimat 5 μg group than in either the tio-
tropium Respimat 2.5 μg group or the tiotropium
Respimat 1.25 μg group. This was due to a marginally
increased number of patients reporting with asthma (3.8%),
rhinitis (2.5%), sinusitis (2.5%) and gastroenteritis (2.5%)
(Table 3). The most commonly experienced AEs were
nasopharyngitis, asthma, bronchitis and pharyngitis, with
the majority of these reported as mild to moderate in in-
tensity. Four serious AEs were experienced by two patients
during the study: pre-syncope was reported in a patient
receiving tiotropium Respimat 5 μg; asthma exacerba-
tions, H1N1 influenza and mycoplasmal pneumonia were
observed in a patient receiving tiotropium Respimat
1.25 μg. The investigators did not consider any of these
serious AEs to be related to the study medication. Both
patients who experienced serious AEs prematurely dis-
continued study medication as a result. No life-threatening
or fatal AEs were reported.
Overall, mean systolic and diastolic blood pressure and
heart rate were comparable between the four treatment
groups at Visit 1 and over 3 h post-dose. No dose-dependent
trends were observed in the tiotropium Respimat treat-
ment groups.Discussion
This is the first placebo-controlled clinical study of tio-
tropium Respimat in adolescent patients with symptomatic
asthma. The clinical findings demonstrate that once-daily
tiotropium, administered via the Respimat SoftMist
inhaler, is an efficacious and well-tolerated bronchodilator
as add-on therapy to ICS for this patient population.
From the efficacy analyses performed in this study, the
preferred dose of once-daily tiotropium Respimat appearsTable 3 Overview of adverse events (treated set).
n (%) Tiotropium Resp
5 μg (n Z 80)
Any AE 18 (22.5)
Type of AEa,b
Nasopharyngitis 2 (2.5)
Asthma 3 (3.8)
Bronchitis 2 (2.5)
Pharyngitis 1 (1.3)
Rhinitis 2 (2.5)
Sinusitis 2 (2.5)
Gastroenteritis 2 (2.5)
Viral infection 0
Any drug-related AEs 0
Serious AEs 1 (1.3)
AEs resulting in discontinuation of study drug 1 (1.3)
AE, adverse event.
a Medical Dictionary for Drug Regulatory Affairs coding system (V 14
b Occurring in 2% of patients in any treatment group.to be 5 μg in adolescent patients with symptomatic asthma.
Results from lung function analyses demonstrated that peak
FEV1(0e3h) (the primary end point), trough FEV1, FEV1
AUC(0e3h) and morning/evening PEF responses for tio-
tropium Respimat 5 μg were superior to those for placebo
Respimat and were greater than those observed with the
two lower doses of tiotropium Respimat. This study pro-
vided an opportunity to evaluate the morning reduction in
PEF experienced by these patients before medication is
taken. Our observations are in line with previous studies in
adult patients with symptomatic asthma in whom signifi-
cant improvements in peak and trough FEV1 and PEF were
reported following once-daily tiotropium Respimat 5 μg
treatment compared with placebo [14,15].
In this dose-ranging study in adolescent patients, all
three doses of tiotropium Respimat were generally well
tolerated, with only a slightly higher incidence of AEs
(asthma, rhinitis, sinusitis and gastroenteritis) reported in
the tiotropium Respimat 5 μg treatment group. There was
no evidence of dose ordering in any preferred term
observed at higher incidence in this treatment group. This
study was designed (short-term and incomplete crossover)
to investigate dose ranging but not safety. Any conclusions
on safety are therefore limited, and long-term or parallel-
group studies are required for further investigation. In the
proof-of-concept Phase II study of tiotropium Respimat
5 μg versus salmeterol or placebo as add-on to ICS for adult
patients with moderate persistent asthma, AEs were well
balanced across treatment groups [13]. Results from long-
term, parallel-group, Phase III studies will be needed to
provide further insight into the safety of tiotropium
Respimat in adolescent patients with asthma. Safety
findings are already available from two Phase III studies of
tiotropium Respimat 5 μg versus placebo Respimat in
adult patients with symptomatic asthma despite ICS plus
LABA [15]. In these studies, AEs were similarly well
balanced across the two treatment groups.
With regard to patient-reported outcomes, ACQ-7 scores
in this study improved during treatment with all threeimat Placebo Respimat
(n Z 75)2.5 μg (n Z 75) 1.25 μg (n Z 75)
10 (13.3) 13 (17.3) 10 (13.3)
3 (4.0) 3 (4.0) 1 (1.3)
0 2 (2.7) 3 (4.0)
2 (2.7) 1 (1.3) 0
0 2 (2.7) 0
1 (1.3) 0 0
0 0 0
0 0 0
0 0 2 (2.7)
0 0 0
0 1 (1.3) 0
0 1 (1.3) 0
.0) preferred term classification.
Tiotropium add-on in adolescents with symptomatic asthma 1275tiotropium Respimat doses and placebo Respimat to
almost the same degree. ACQ-7 is an exploratory tool, and
evaluation of findings may be limited by the observed large
placebo effect due to trial procedures leading to improved
compliance, which reduces the possibility of achieving a
clinically significant treatment effect in a short-term
duration study. In addition, the crossover design of this
study with no washout periods impairs the discriminating
ability of the study. Further long-term studies are required
to more fully understand the patient-reported outcomes
associated with tiotropium Respimat in adolescents as
well as in adults.
The decision to use an incomplete crossover design for
this study was driven by the wish to reduce the treatment
burden on patients compared with a full crossover study.
Although slightly more patients are required in an incom-
plete crossover study, the sample size is still relatively
small compared with a parallel-group study. By assigning an
equal number of patients to each treatment group, the
period effect (the order in which the study drug was
administered) was minimised. Washout periods were not
included between treatment periods as these can desta-
bilise patients. A 4-week treatment period was used, as
steady-state tiotropium is reached after at least 3 weeks
[19]. It is important to note that there were no safety
concerns during the placebo treatment period as patients
continued receiving background ICS and were supplied with
short-acting b2-agonist rescue medication. Lastly, patients
must have received a stable maintenance ICS dose for at
least 4 weeks prior to screening and during the 4-week run-
in period, facilitating a steady state that was equally likely
to improve compliance in all arms during the treatment
period.
Based on efficacy and safety evaluations from this
randomised, placebo-controlled, dose-ranging study, the
preferred dose of tiotropium Respimat add-on therapy to
maintenance treatment with ICS in adolescents with mod-
erate persistent asthma appears to be once-daily 5 μg,
which is consistent with findings from studies of tiotropium
Respimat therapy for adult asthma patients. However, the
study population was rather limited with regard to safety
recording and, due to the study design, long-term safety
and tolerability could not be investigated.
Based on the results from this study, further investiga-
tion of the tiotropium Respimat 5 μg dose added on to ICS
maintenance therapy is justified in a larger adolescent
population, and evaluation of tiotropium Respimat in
children younger than 12 years should be considered, as a
therapeutic benefit is anticipated in this patient popula-
tion. Two long-term, randomised, double-blind, placebo-
controlled, parallel-group, Phase III studies of tiotropium
Respimat add-on to ICS maintenance therapy in adult
patients with moderate persistent asthma have been con-
ducted (NCT01172808 and NCT01172821). These studies
investigated tiotropium (once-daily 5 μg and 2.5 μg via the
Respimat SoftMist inhaler) versus placebo Respimat,
and exploratory comparisons with an active comparator
(salmeterol), with the aim of providing further information
on long-term safety and efficacy, including clinical out-
comes, relevant for both adult and adolescent patients. In
addition, a 1-year, randomised, double-blind, placebo-
controlled, parallel-group, Phase III study (NCT01257230) inadolescent patients with moderate persistent asthma,
symptomatic despite ICS, is currently investigating two
doses of tiotropium (once-daily 5 μg and 2.5 μg via the
Respimat SoftMist inhaler) compared with placebo
Respimat over a treatment period of 48 weeks.Conflicts of interest
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